LIFECORE BIOMEDICAL, INC. Unrealized Gain (Loss) on Derivatives
LIFECORE BIOMEDICAL, INC. (LFCR) reported Unrealized Gain (Loss) on Derivatives of -$4.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for the quarter ending 2026-06-30 was -$1.20M.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for the quarter ending 2026-03-31 was -$3.15M.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was -$375.00K.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for the quarter ending 2025-05-25 was -$1.09M.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for fiscal 2025 was $409.00K, a 98.96% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for fiscal 2024 was $39.50M.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for fiscal 2023 was $0.00.
- LIFECORE BIOMEDICAL, INC. unrealized gain (loss) on derivatives for fiscal 2022 was $0.00.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 7 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.36M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$3.15M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | -$1.57M 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | -$375.00K 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.69M 10-Q · filed 2026-08-05 | -$491.00K derived: sum of 3 quarters · filed 2026-08-05 | $409.00K 10-KT · filed 2026-03-16 | |
| 2025-02-23 | -$600.00K 10-Q · filed 2026-05-06 | $600.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.50M 10-Q · filed 2025-04-03 | -$900.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-11-24 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | $2.10M 10-Q · filed 2025-01-02 | -$300.00K derived: sum of 3 quarters · filed 2026-03-16 | $20.70M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-08-25 | $900.00K 10-Q · filed 2025-11-06 | -$1.50M derived: sum of 2 quarters · filed 2026-03-16 | $19.50M derived: sum of 3 quarters · filed 2026-03-16 | $40.20M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-05-26 | -$2.40M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $18.60M derived: sum of 2 quarters · filed 2026-03-16 | $39.30M derived: sum of 3 quarters · filed 2026-03-16 | $39.50M 10-KT · filed 2026-03-16 | |
| 2024-02-25 | $21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-03 | $41.70M derived: sum of 2 quarters · filed 2025-04-03 | $41.90M 10-Q · filed 2025-04-03 | $41.90M derived: sum of 4 quarters · filed 2025-04-03 | |
| 2023-11-26 | $20.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | $20.90M 10-Q · filed 2025-01-02 | $20.90M derived: sum of 3 quarters · filed 2025-01-02 | $20.90M derived: sum of 4 quarters · filed 2025-01-02 | |
| 2023-08-27 | $200.00K 10-Q · filed 2024-10-04 | $200.00K derived: sum of 2 quarters · filed 2024-10-04 | $200.00K derived: sum of 3 quarters · filed 2024-10-04 | $200.00K derived: sum of 4 quarters · filed 2024-10-04 | |
| 2023-05-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $0.00 derived: sum of 2 quarters · filed 2024-08-26 | $0.00 derived: sum of 3 quarters · filed 2024-08-26 | $0.00 10-K · filed 2024-08-26 | |
| 2023-02-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | $0.00 derived: sum of 2 quarters · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||
| 2022-11-27 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | |||
| 2022-08-28 | $0.00 10-Q · filed 2024-08-09 | ||||
| 2022-05-29 | $0.00 10-K · filed 2024-08-26 | ||||
| 2012-02-26 | $53.00K 10-Q · filed 2013-04-04 | $159.00K derived: sum of 2 quarters · filed 2013-04-04 | $100.00K 10-Q · filed 2013-04-04 | ||
| 2011-11-27 | $106.00K 10-Q · filed 2013-01-04 | $52.00K 10-Q · filed 2013-01-04 | |||
| 2011-08-28 | -$54.00K 10-Q/A · filed 2013-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |